Vaccines targeting IgE in the treatment of asthma and allergy

Human Vaccines

Volumn 5, Issue 5, 2009, Pages 302-309

  Peng, Zhikang ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Allergy; Asthma; Atopy; IgE; Vaccine

Indexed keywords

CHIMERIC IMMUNOGLOBULIN E VACCINE; DACLIZUMAB; ETANERCEPT; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E PEPTIDE KLH; IMMUNOGLOBULIN FC FRAGMENT; IMMUOGLOBULIN E PEPTIDE BASED VACCINE; IMMUOGLOBULIN E VACCINE; INFLIXIMAB; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4 RECEPTOR; KELIXIMAB; LERDELIMUMAB; LUMILIXIMAB; MEPOLIZUMAB; METELIMUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ALLERGY; ANAPHYLAXIS; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ASTHMA; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG COST; DRUG HALF LIFE; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MAST CELL DEGRANULATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIMARY TUMOR; REVIEW; SERUM SICKNESS; VIRUS PARTICLE;

ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; VACCINES;

EID: 70349556026     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.5.7442     Document Type: Review

References (91)

1. NHLBI/WHO. Global initiative for asthma: Global strategy for asthma management and prevention http://www.ginasthma.com 2003.
2. Kaur B, Anderson HR, Austin J, Burr M, Harkins LS, Strachan DP, et al. Prevalence of asthma symptoms, diagnosis and treatment in 12-14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK). BMJ 1998; 316:118-24.
3. Asher I, Boner A, Chuchalin A, Custovic A, Dagli E, Haus M, et al. Prevention of allergy and asthma: Interim report. Allergy 2000; 55:1069-88.
4. Upton MN, McConnachie A, McSharry C, Hart CL, Smith GD, Gillis CR, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: The Midspan family study surveys of parents and offspring. BMJ 2000; 321:88-92.
5. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-43.
6. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003; 112:252-62.
7. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma - European network for understanding mechanisms of severe asthma. Eur Respir J 2003; 22:470-7.
8. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
9. Cohn L, Elias JA, Chupp GL. Asthma: Mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22:789-815.
10. Sunyer J, Anto JM, Sabria J, Roca J, Morell F, Rodriguez-Roisin R, et al. Relationship between serum IgE and airway responsiveness in adults with asthma. J Allergy Clin Immunol 1995; 95:699-706.
11. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:271-7.
12. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067-71.
13. Naqvi M, Choudhry S, Tsai HJ, Thyne S, Navarro D, Nazario S, et al. Association between IgE levels and asthma severity among African American, Mexican and Puerto Rican patients with asthma. J Allergy Clin Immunol 2007; 120:137-43.
14. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005; 60:350-3.
15. Delves PJ, Martin DJ, Burton DR, Roitt IM. In: Roitt's essential immunology; 11th ed. Oxford: Blackwell Science, 2006:; 344-7.
16. Ballow M. Biologic immune modifiers: Trials and tribulations - are we there yet? J Allergy Clin Immunol 2006; 118:1209-15.
17. Holgate ST, Holloway J, Wilson S, Howarth PH, Haitchi HM, Babu S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006; 117:496-506.
18. Wagelie-Steffen AL, Kavanaugh AF, Wasserman SI. Biologic therapies for the treatment of asthma. Clin Chest Med 2006; 27:133-47.
19. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34:819-36.
20. Howell JE, McAnulty RJ. TGFbeta: Its role in asthma and therapeutic potential. Curr Drug Targets 2006; 7:547-65.
21. Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966; 97:75-85.
22. Ishizaka, T, Mechanisms of IgE mediated hypersensitivity. In: Middleton E, et al.: Allergy: Principles and Practice. Mosby Co., St. Louis, Missouri, 1988.
23. Joseph M, Gounni AS, Kusnierz JP, Vorng H, Sarfati M, Kinet JP, et al. Expression and functions of the high-affinity IgE receptor on human platelets and megakaryocyte precursors. Eur J Immunol 1997; 27:2212-8.
24. Kinet JP. The high-affinity IgE receptor (FcepsilonRI): From physiology to pathology. Annu Rev Immunol 1999; 17:931-72.
25. Gounni AS, Lamkhioued B, Koussih L, Ra C, Renzi PM, Hamid Q. Human neutrophils express the high-affinity receptor for immunoglobulin E (FcepsilonRI): Role in asthma. Faseb J 2001; 15:940-9.
26. Novak N, Bieber T, Kraft S. Immunoglobulin E-bearing antigen-presenting cells in atopic dermatitis. Curr Allergy Asthma Rep 2004; 4:263-9.
27. Gounni AS, Wellemans V, Yang J, Bellesort F, Kassiri K, Gangloff S, et al. Human airway smooth muscle cells express the high affinity receptor for IgE (FcepsilonRI): A critical role of FcepsilonRI in human airway smooth muscle cell function. J Immunol 2005; 175:2613-21.
28. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7:365-78.
29. Gounni AS. The high-affinity IgE receptor (FcepsilonRI): A critical regulator of airway smooth muscle cells? Am J Physiol Lung Cell Mol Physiol 2006; 291:312-21.
30. Asai K, Kitaura J, Kawakami Y, Yamagata N, Tsai M, Carbone DP, et al. Regulation of mast cell survival by IgE. Immunity 2001; 14:791-800.
31. Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, Siraganian RP, et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 2001; 14:801-11.
32. Kitaura J, Song J, Tsai M, Asai K, Maeda-Yamamoto M, Mocsai A, et al. Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci USA 2003; 100:12911-6.
33. Katoh N, Kraft S, Wessendorf JH, Bieber T. The high-affinity IgE receptor (FcepsilonRI) blocks apoptosis in normal human monocytes. J Clin Invest 2000; 105:183-90.
34. Saffar AS, Alphonse MP, Shan L, Hayglass KT, Simons FE, Gounni AS. IgE modulates neutrophil survival in asthma: Role of mitochondrial pathway. J Immunol 2007; 178:2535-41.
35. Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341:1966-73.
36. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-90.
37. Johansson SG, Haahtela T, O'Byrne PM. Omalizumab and the immune system: An overview of preclinical and clinical data. Ann Allergy Asthma Immunol 2002; 89:132-8.
38. Babu KS, Holgate ST. The role of anti-IgE therapies in the treatment of asthma. Hosp Med 2002; 63:483-6.
39. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91:182-8.
40. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378-86.
41. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-8.
42. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-16.
43. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35:408-16.
44. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117:1493-9.
45. Prenner BM. Asthma 2008: Targeting immunoglobulin E to achieve disease control. J Asthma 2008; 45:429-36.
46. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Downregulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438-45.
47. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FcepsilonRI expression and function. J Allergy Clin Immunol 2004; 114:527-30.
48. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003; 112:1147-54.
49. Chang TW, Shiung YY. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 2006; 117:1203-12.
50. Hamelmann E. The rationale for treating allergic asthma with anti-IgE. Eur Respir Rev 2007; 16:61-6.
51. Buhl R. Anti-IgE: Lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy. Eur Respir Rev 2007; 16:73-7.
52. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 2006; 96:624-7.
53. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120:1378-81.
54. US Food and Drug Administration. Center for Biologics Evaluation and Research. BAL STN 103976/0. Rockville (MD): Department of Health and Human Services 2003.
55. Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007; 120:972-3.
56. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91:154-9.
57. Zagury D, Gallo RC. Anti-cytokine Ab immune therapy: Present status and perspectives. Drug Discovery Today 2004; 9:72-81.
58. Zagury D, Le Buanec H, Bizzini B, Burny A, Lewis G, Gallo RC. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev 2003; 14:123-37.
59. Zuany-Amorim C, Manlius C, Dalum I, Jensen MR, Gautam A, Pay G, et al. Induction of TNFalpha autoantibody production by AutoVac TNF106: A novel therapeutic approach for the treatment of allergic diseases. Int Arch Allergy Immunol 2004; 133:154-63.
60. Rohn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006; 36:2857-67.
61. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006; 36:2868-74.
62. Le Buanec H, Delavallee L, Bessis N, Paturance S, Bizzini B, Gallo R, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 2006; 103:19442-7.
63. Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 2007; 104:2837-42.
64. Vernersson M, Ledin A, Johansson J, Hellman L. Generation of therapeutic antibody responses against IgE through vaccination. Faseb J 2002; 16:875-7.
65. Wang CY, Walfield AM, Fang X, Hammerberg B, Ye J, Li ML, et al. Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine 2003; 21:1580-90.
66. Ma Y, Hayglass KT, Becker AB, Fan Y, Yang X, Basu S, et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 2007; 176:439-45.
67. Ma Y, HayGlass KT, Becker AB, Halayko AJ, Basu S, Simons FER, et al. Novel cytokine peptide-based vaccines: An interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy 2007; 62:675-82.
68. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem 2008.
69. Marshall JS, Bell EB. Induction of an auto-anti-IgE response in rats I. Effects on serum IgE concentrations. Eur J Immunol 1985; 15:272-7.
70. Marshall JS, Bell EB. Induction of an auto-anti-IgE response in rats III. Inhibition of a specific IgE response. Immunology 1989; 66:428-33.
71. Marshall JS, Prout SJ, Jaffery G, Bell EB. Induction of an auto-anti-IgE response in rats II. Effects on mast cell populations. Eur J Immunol 1987; 17:445-51.
72. Hellman L. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Immunol 1994; 24:415-20.
73. Johansson J, Hellman L. Modifications increasing the efficacy of recombinant vaccines: Marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine. Vaccine 2007; 25:1676-82.
74. Stanworth DR, Jones VM, Lewin IV, Nayyar S. Allergy treatment with a peptide vaccine. Lancet 1990; 336:1279-81.
75. Stadler BM, Rudolf MP, Vogel M, Miescher S, Zurcher AW, Kricek F. Can active immunization redirect an anti-IgE immune response? Int Arch Allergy Immunol 1997; 113:216-8.
76. Stadler BM, Zurcher AW, Miescher S, Kricek F, Vogel M. Mimotope and anti-idiotypic vaccines to induce an anti-IgE response. Int Arch Allergy Immunol 1999; 118:119-21.
77. Peng Z, Liu Q, Wang Q, Rector E, Ma Y, Warrington R. Novel IgE peptide-based vaccine prevents the increase of IgE and downregulates elevated IgE in rodents. Clin Exp Allergy 2007; 37:1040-8.
78. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, Kundig T, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002; 20:3104-12.
79. Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001; 108:415-23.
80. Cooper PJ, Chico ME, Sandoval C, Espinel I, Guevara A, Kennedy MW, et al. Human infection with Ascaris lumbricoides is associated with a polarized cytokine response. J Infect Dis 2000; 182:1207-13.
81. Male D, Brostoff J, Roth DB, Roitt I. Immunology In: 7th ed. [s.l.]: Mosby-Elsevier, 2006; 445-6.
82. Amiri P, Haak-Frendscho M, Robbins K, McKerrow JH, Stewart T, Jardieu P. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med 1994; 180:43-51.
83. Marshall JS, Wells PD, Bell EB. Accelerated elimination of N. brasiliensis from the small intestine after auto-anti-IgE induction. Immunology 1987; 60:303-8.
84. Butterworth AE, Dunne DW, Fulford AJ, Thorne KJ, Gachuhi K, Ouma JH, et al. Human immunity to Schistosoma mansoni: Observations on mechanisms, and implications for control. Immunol Invest 1992; 21:391-407.
85. Atkins NS, Conway DJ, Lindo JF, Bailey JW, Bundy DA. L3 antigen-specific antibody isotype responses in human strongyloidiasis: Correlations with larval output. Parasite Immunol 1999; 21:517-26.
86. McSharry C, Xia Y, Holland CV, Kennedy MW. Natural immunity to Ascaris lumbricoides associated with immunoglobulin E antibody to ABA-1 allergen and inflammation indicators in children. Infect Immun 1999; 67:484-9.
87. Watanabe N, Bruschi F, Korenaga M. IgE: A question of protective immunity in Trichinella spiralis infection. Trends Parasitol 2005; 21:175-8.
88. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial. JAMA 2001; 286:2956-67.
89. Finkelman FD, Urban JF Jr. The other side of the coin: The protective role of the TH2 cytokines. J Allergy Clin Immunol 2001; 107:772-80.
90. Male D, Brostoff J, Roth DB, Roitt I. Immunology In: 7th ed.: Mosby-Elsevier, 2006; Male; 427.
91. Dalum I, Butler DM, Jensen MR, Hindersson P, Steinaa L, Waterston AM, et al. Therapeutic antibodies elicited by immunization against TNFalpha. Nature biotechnology 1999; 17:666-9.